Testing pelacarsen for high Lp(a) in heart disease patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new medicine called pelacarsen for people with very high Lp(a) (a type of cholesterol) and existing heart or blood vessel disease. It aims to see if adding pelacarsen to your current cholesterol treatment can lower your Lp(a) levels further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a history of heart disease, stroke, or artery disease in your legs.
- You are currently on a stable dose of cholesterol-lowering medicine for at least 30 days.
- Your Lp(a) level (a type of cholesterol) is 175 nmol/L or higher.
- Your LDL (bad cholesterol) is still above 70 mg/dL despite current treatment.
- You have not taken inclisiran before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called muvalaplin that lowers a specific type of cholesterol linked to heart disease. It aims to see if muvalaplin can reduce the risk of future heart attacks, strokes, or related procedures in people with high levels of this cholesterol.
This program provides access to pelacarsen (TQJ230) for patients with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. It aims to offer potential benefit when standard therapies are not suitable.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This trial is for people who have already finished taking pelacarsen in a previous study. It offers continued access to the drug and checks long-term safety.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This trial tests if olpasiran can lower a type of cholesterol called Lp(a) to help prevent a first major heart attack, stroke, or other heart problems. It is for people at higher risk due to risk factors or early signs of artery disease, but who have not yet had a heart attack or stroke.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.